©2024 Stanford Medicine
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Not Recruiting
Trial ID: NCT00398372
Purpose
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism
of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
Official Title
Le20: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Stanford Investigator(s)
Wen-Kai Weng, MD, PhD
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology
Ronald Levy, MD
Robert K. and Helen K. Summy Professor in the School of Medicine
Eligibility
Inclusion Criteria:Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Intervention(s):
drug: Rituximab
drug: Epratuzumab
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Mayita Romero
6507256452